<p>This is a summary of the European public assessment report (EPAR) for Oxervate. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Oxervate.</p><p>For practical information about using Oxervate, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults</p></div>
Therapeutic Area (MeSH)
ATC Code
S01
ATC Item
N/A
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| recombinant human nerve growth factor | N/A | recombinant human nerve growth factor |
EMA Name
Oxervate
Medicine Name
Oxervate
Aliases
N/ANo risk management plan link.
